(thirdQuint)Clinical Evaluation of T.

R.

U.

E.

 TEST Panel 3.

2 in Children and Adolescents.

 The study population will include at least 100 consecutive subjects 6-17 years of age with suspected contact dermatitis based on symptoms and clinical history.

 Study subjects must be otherwise healthy and fulfill entry criteria.

 Visit 1 (Day 0): Informed Consent, Inclusion/Exclusion Criteria Assessment, Medical and Medicine History, Pregnancy Test (for female subjects of child-bearing potential), Panel Placement.

Visit 2 (Day 2): Panel Removal, Panel Adhesion and Irritation Assessment, AE and Concomitant Medication Review.

Visit 3 (Day 3- approximately 72 hours after placement): Skin Reactions Assessed and Scored.

 Adverse Event and Concomitant Medication Review.

Visit 4 (Day 4 approximately 96 hours after placement): Skin Reactions Assessed and Scored.

 Adverse Event and Concomitant Medication Review.

Visit 5 (Day 71): Skin Reaction Assessed and Scored.

 AE and Concomitant Medication Review.

 Visit 6 (Day 212): Skin Reaction Assessed and Scored.

 AE and Concomitant Medication Review.

 Visit performed via phone call, unless investigator determines that subject should be seen in clinic.

 Primary Endpoint: Frequency and characterization of positive reactions per allergen.

 Secondary Endpoint: Prevalence of late or persistent reactions, irritation, adhesion, subject-reported itching or burning, and adverse events.

.

 Clinical Evaluation of T.

R.

U.

E.

 TEST Panel 3.

2 in Children and Adolescents@highlight

To evaluate the diagnostic performance (primary) and safety (secondary) of seven T.

R.

U.

E.

 Test Panel 3.

2 allergens: Gold sodium thiosulfate, Hydrocortisone-17-butyrate, Bacitracin, Parthenolide, Methyldibromoglutaronitrile, Disperse blue 106, and Bronopol in pediatric subjects 6-18 years of age with suspected contact dermatitis based on symptoms and clinical history.

